Blue Care Network to launch precision medicine program

351
Photo by iStock

A Michigan health insurance agency is launching a personalized medicine program.

Blue Care Network of Blue Cross Blue Shield of Michigan announced Tuesday, April 6, its plans for Blue Cross Personalized Medicine, a form of precision care that will use pharmacogenomics, or genetic testing, to personalize treatments for select members.

A pilot program now is underway for select members through the end of 2022, with a full launch scheduled for January 2023 for eligible Blue Care Network members with pharmacy benefits.

Dr. Scott Betzelos, chief medical officer of Blue Care Network and vice president of HMO strategy and affordability, said the program is a real opportunity to address health care needs on an individual basis.

“Our first priority with the Blue Cross Personalized Medicine program is to ensure that a physician is able to provide the right medication, at the right dose, as early in the process as possible,” Betzelos said. “Working closely with our members and their physicians, we are now able to cut out the guess work and make informed decisions that lead to sustainable treatment options and better patient outcomes.”

Blue Care Network has partnered with the precision medicine company OneOme to facilitate the new program. OneOme will provide testing, reporting and analytics to use in areas such as behavioral health, oncology, pain management and cardiology.

Each patient and physician will receive a personalized clinical action plan prepared by a trained pharmacogenomic pharmacist to incorporate test results into actionable steps. Any medications or regimen changes are optional, and test results are not shared with Blue Care Network.

“We understand and respect the sensitivity that people have when it comes to protecting their genetic information, and we have built robust protections into our program,” Betzelos said.

Blue Cross Personalized Medicine will be provided at no additional cost to members or employer group customers.

Facebook Comments